Transderm Scop Articles
Cephalon to acquire Anesta in $444M deal
18 July 2000
FDA rejects Nastech's New Drug Application for motion sickness drug
24 February 2000
Nastech files NDA for intranasal scopolamine
21 December 1999
Nastech to file NDA for motion sickness drug
12 July 1999
Novartis To Relaunch Scopolamine Patches
13 November 1997
Noven Files Two INDs
16 October 1997
Cognitive Enhancers Unveiled At ASM
21 November 1994
Showing 1-7 of 7 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
